Allogene Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Allogene Therapeutics, Inc. (ALLO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.44M, a 43.24% increase year-over-year.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.27M, a 32.07% decline year-over-year.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.65M, a 35.37% decline year-over-year.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $8.69M, a 35.95% decline year-over-year.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $37.64M, a 27.25% decline from fiscal 2024.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $51.74M, a 21.54% decline from fiscal 2023.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $65.95M, a 21.11% decline from fiscal 2022.
- Allogene Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $83.60M, a 3.44% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.44M 10-Q · filed 2026-08-12 | $20.71M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $8.27M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $37.64M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $8.65M 10-Q · filed 2025-11-06 | $17.34M derived: sum of 2 quarters · filed 2026-08-12 | $29.51M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $8.69M 10-Q · filed 2026-08-12 | $20.86M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $12.18M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $51.74M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $13.39M 10-Q · filed 2025-11-06 | $26.95M derived: sum of 2 quarters · filed 2025-11-06 | $38.87M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $13.56M 10-Q · filed 2025-11-06 | $25.48M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $11.92M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $65.95M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $15.35M 10-Q · filed 2024-11-07 | $31.95M derived: sum of 2 quarters · filed 2024-11-07 | $50.72M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $16.59M 10-Q · filed 2024-11-07 | $35.36M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $18.77M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $83.60M 10-K/A · filed 2024-03-14 | |||
| 2022-09-30 | $21.15M 10-Q · filed 2023-11-02 | $44.04M derived: sum of 2 quarters · filed 2023-11-02 | $66.35M derived: sum of 3 quarters · filed 2023-11-02 | $88.39M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $22.89M 10-Q · filed 2023-11-02 | $45.21M 10-Q · filed 2022-08-09 | $67.24M derived: sum of 3 quarters · filed 2024-03-14 | $88.10M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $22.32M 10-Q · filed 2023-11-02 | $44.35M derived: sum of 2 quarters · filed 2024-03-14 | $65.21M derived: sum of 3 quarters · filed 2024-03-14 | $86.34M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $22.04M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $42.89M derived: sum of 2 quarters · filed 2024-03-14 | $64.03M derived: sum of 3 quarters · filed 2024-03-14 | $80.82M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $20.86M 10-Q · filed 2022-11-02 | $41.99M derived: sum of 2 quarters · filed 2022-11-02 | $58.78M 10-Q · filed 2021-11-04 | $75.23M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | $21.13M 10-Q · filed 2022-11-02 | $37.93M 10-Q · filed 2022-08-09 | $54.38M derived: sum of 3 quarters · filed 2024-03-14 | $72.20M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | $16.79M 10-Q · filed 2022-11-02 | $33.24M derived: sum of 2 quarters · filed 2024-03-14 | $51.07M derived: sum of 3 quarters · filed 2024-03-14 | $67.84M derived: sum of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | $16.45M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $34.28M derived: sum of 2 quarters · filed 2024-03-14 | $51.05M derived: sum of 3 quarters · filed 2024-03-14 | $65.26M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $17.82M 10-Q · filed 2021-11-04 | $34.59M derived: sum of 2 quarters · filed 2021-11-04 | $48.81M 10-Q · filed 2021-11-04 | $62.68M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $16.77M 10-Q · filed 2021-08-04 | $30.98M 10-Q · filed 2021-08-04 | $44.86M derived: sum of 3 quarters · filed 2022-02-23 | $57.69M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $14.21M 10-Q · filed 2021-05-05 | $28.09M derived: sum of 2 quarters · filed 2022-02-23 | $40.92M derived: sum of 3 quarters · filed 2022-02-23 | $52.41M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $13.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $26.71M derived: sum of 2 quarters · filed 2022-02-23 | $38.20M derived: sum of 3 quarters · filed 2022-02-23 | $46.06M 10-K · filed 2022-02-23 |
| 2019-09-30 | $12.84M 10-Q · filed 2020-11-04 | $24.32M derived: sum of 2 quarters · filed 2020-11-04 | $32.19M 10-Q · filed 2020-11-04 | $38.06M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $11.49M 10-Q · filed 2020-08-05 | $19.35M 10-Q · filed 2020-08-05 | $25.23M derived: sum of 3 quarters · filed 2021-02-25 | $29.86M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $7.87M 10-Q · filed 2020-05-06 | $13.74M derived: sum of 2 quarters · filed 2021-02-25 | $18.38M derived: sum of 3 quarters · filed 2021-02-25 | $26.43M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $10.51M derived: sum of 2 quarters · filed 2021-02-25 | $18.57M derived: sum of 3 quarters · filed 2021-02-25 | $18.57M 10-K · filed 2021-02-25 |
| 2018-09-30 | $4.64M 10-Q · filed 2019-11-05 | $12.70M derived: sum of 2 quarters · filed 2019-11-05 | $12.70M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $8.06M 10-Q · filed 2019-08-07 | $8.06M 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |